In the latest deal in a resurgent space, Eisai announced Monday it would pay Bliss Biopharmaceutical up to $2 billion in a clinical trial collaboration for an antibody-drug conjugate carrying its chemotherapy drug Halaven (eribulin).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,